SK287779B6 - Liečivo na liečenie karcinómu prsníka obsahujúce fulvestrant - Google Patents

Liečivo na liečenie karcinómu prsníka obsahujúce fulvestrant Download PDF

Info

Publication number: SK287779B6
Authority: SK; Slovakia
Prior art keywords: treatment; fulvestrant; lesions; study; patients
Prior art date: 2000-04-05

Application number

SK1429-2002A

Other languages

English (en)

Slovak (sk)

Other versions

SK14292002A3 (sk

Inventor

Beat Thurlimann

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-05

Filing date

2001-04-02

Publication date

2011-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287779(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-08-05 Publication of SK14292002A3 publication Critical patent/SK14292002A3/sk

2011-09-05 Publication of SK287779B6 publication Critical patent/SK287779B6/sk

Links

238000011282 treatment Methods 0.000 title claims abstract description 82
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims abstract description 57
229960002258 fulvestrant Drugs 0.000 title claims abstract description 52
206010006187 Breast cancer Diseases 0.000 title claims abstract description 38
208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 34
239000003814 drug Substances 0.000 title claims abstract description 12
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims abstract description 33
239000003886 aromatase inhibitor Substances 0.000 claims abstract description 18
229960001603 tamoxifen Drugs 0.000 claims abstract description 16
229940122815 Aromatase inhibitor Drugs 0.000 claims abstract description 14
238000002360 preparation method Methods 0.000 claims abstract description 8
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical group N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 20
229960002932 anastrozole Drugs 0.000 claims description 19
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 19
229960003881 letrozole Drugs 0.000 claims description 18
238000010255 intramuscular injection Methods 0.000 claims description 5
239000007927 intramuscular injection Substances 0.000 claims description 4
230000003902 lesion Effects 0.000 description 53
230000004044 response Effects 0.000 description 44
206010028980 Neoplasm Diseases 0.000 description 37
238000011156 evaluation Methods 0.000 description 34
201000010099 disease Diseases 0.000 description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
206010061818 Disease progression Diseases 0.000 description 22
230000005750 disease progression Effects 0.000 description 22
239000000203 mixture Substances 0.000 description 21
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 18
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 18
238000002591 computed tomography Methods 0.000 description 18
238000009472 formulation Methods 0.000 description 18
206010061728 Bone lesion Diseases 0.000 description 17
229960003437 aminoglutethimide Drugs 0.000 description 16
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 16
239000008194 pharmaceutical composition Substances 0.000 description 15
230000036961 partial effect Effects 0.000 description 13
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
238000007469 bone scintigraphy Methods 0.000 description 10
239000000262 estrogen Substances 0.000 description 10
238000002595 magnetic resonance imaging Methods 0.000 description 10
239000000333 selective estrogen receptor modulator Substances 0.000 description 10
229940095743 selective estrogen receptor modulator Drugs 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
230000000694 effects Effects 0.000 description 9
229940011871 estrogen Drugs 0.000 description 9
239000000328 estrogen antagonist Substances 0.000 description 9
102000015694 estrogen receptors Human genes 0.000 description 9
108010038795 estrogen receptors Proteins 0.000 description 9
JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 9
229940122361 Bisphosphonate Drugs 0.000 description 8
230000002411 adverse Effects 0.000 description 8
229940046836 anti-estrogen Drugs 0.000 description 8
230000001833 anti-estrogenic effect Effects 0.000 description 8
150000004663 bisphosphonates Chemical class 0.000 description 8
238000012216 screening Methods 0.000 description 8
230000003637 steroidlike Effects 0.000 description 8
230000008901 benefit Effects 0.000 description 7
230000008859 change Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000000155 isotopic effect Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
230000002018 overexpression Effects 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
108700012941 GNRH1 Proteins 0.000 description 6
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 6
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
206010066901 Treatment failure Diseases 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
229940087861 faslodex Drugs 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
229940066675 ricinoleate Drugs 0.000 description 5
WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 5
210000000115 thoracic cavity Anatomy 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
108010082126 Alanine transaminase Proteins 0.000 description 4
208000020084 Bone disease Diseases 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229940046844 aromatase inhibitors Drugs 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
230000003054 hormonal effect Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000000010 osteolytic effect Effects 0.000 description 4
208000037821 progressive disease Diseases 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000002604 ultrasonography Methods 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
206010006002 Bone pain Diseases 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
238000011360 adjunctive therapy Methods 0.000 description 3
230000001270 agonistic effect Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
229960002903 benzyl benzoate Drugs 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
239000003921 oil Substances 0.000 description 3
238000009806 oophorectomy Methods 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
-1 4,4,5,5,5-pentafluoropentylsulfinyl Chemical group 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
206010055113 Breast cancer metastatic Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
206010027457 Metastases to liver Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000005250 Spontaneous Fractures Diseases 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
238000013176 antiplatelet therapy Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000009164 estrogen replacement therapy Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000012151 immunohistochemical method Methods 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000007434 lytic lesion Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
230000001582 osteoblastic effect Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
239000000583 progesterone congener Substances 0.000 description 2
108090000468 progesterone receptors Proteins 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000013517 stratification Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000002618 waking effect Effects 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010019842 Hepatomegaly Diseases 0.000 description 1
101000889443 Homo sapiens Trefoil factor 1 Proteins 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
206010025102 Lung infiltration Diseases 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010025282 Lymphoedema Diseases 0.000 description 1
241000489861 Maximus Species 0.000 description 1
206010027452 Metastases to bone Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010034156 Pathological fracture Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
102100025803 Progesterone receptor Human genes 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
206010067868 Skin mass Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
102100039175 Trefoil factor 1 Human genes 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940078010 arimidex Drugs 0.000 description 1
238000000222 aromatherapy Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000009850 completed effect Effects 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
229940087476 femara Drugs 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229940074928 isopropyl myristate Drugs 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
229940075495 isopropyl palmitate Drugs 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
208000002502 lymphedema Diseases 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000005015 mediastinal lymph node Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229940085033 nolvadex Drugs 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000002601 radiography Methods 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960003656 ricinoleic acid Drugs 0.000 description 1
FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
229960001023 tibolone Drugs 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
208000037911 visceral disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1429-2002A 2000-04-05 2001-04-02 Liečivo na liečenie karcinómu prsníka obsahujúce fulvestrant SK287779B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008172.9A GB0008172D0 (en)	2000-04-05	2000-04-05	Therapy
PCT/GB2001/001500 WO2001074366A1 (en)	2000-04-05	2001-04-02	Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number	Publication Date
SK14292002A3 SK14292002A3 (sk)	2003-08-05
SK287779B6 true SK287779B6 (sk)	2011-09-05

Family

ID=9889101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1429-2002A SK287779B6 (sk)	2000-04-05	2001-04-02	Liečivo na liečenie karcinómu prsníka obsahujúce fulvestrant

Country Status (29)

Country	Link
US (2)	US20030158166A1 (es)
EP (2)	EP1272195B1 (es)
JP (1)	JP2003528919A (es)
KR (1)	KR100757764B1 (es)
CN (1)	CN1431905A (es)
AT (1)	ATE306270T1 (es)
AU (2)	AU2001244372B2 (es)
BR (1)	BR0109789A (es)
CA (1)	CA2403608A1 (es)
CH (1)	CH1272195H1 (es)
CZ (1)	CZ303096B6 (es)
DE (1)	DE60113975T2 (es)
DK (1)	DK1272195T3 (es)
EE (1)	EE05026B1 (es)
ES (1)	ES2248300T3 (es)
GB (1)	GB0008172D0 (es)
HK (1)	HK1051498A1 (es)
HU (1)	HU230064B1 (es)
IL (2)	IL151932A0 (es)
IS (1)	IS2869B (es)
MX (1)	MXPA02009744A (es)
NO (1)	NO329949B1 (es)
NZ (1)	NZ539603A (es)
PL (1)	PL201175B1 (es)
RU (1)	RU2265438C2 (es)
SK (1)	SK287779B6 (es)
UA (1)	UA80388C2 (es)
WO (1)	WO2001074366A1 (es)
ZA (1)	ZA200207538B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2453111A1 (en) *	2001-07-07	2003-01-23	Alan Marshall Irving	Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) *	2005-09-27	2013-10-15	Robert Benson Aylor	Suppression and prevention of tumors
JP5256042B2 (ja) *	2005-11-22	2013-08-07	インサイト・コーポレイション	癌の処置のための併用療法
WO2007143600A2 (en) *	2006-06-05	2007-12-13	Incyte Corporation	Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
MX2013013104A (es) *	2011-05-09	2014-10-15	Univ Virginia Patent Found	Composiciones y metodos para el tratamiento de cancer.
BR112013029758A2 (pt)	2011-05-20	2018-10-09	Capital, Business Y Gestion De Finanzas S.L.	composição farmacêutica
EP3092027A4 (en) *	2014-01-10	2017-09-06	Atossa Genetics Inc.	Transpapillary methods and compositions for diagnosing and treating breast conditions
WO2019051416A1 (en)	2017-09-11	2019-03-14	Atossa Genetics Inc.	METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN
AU2019274815A1 (en) *	2018-05-24	2021-01-21	Shivanka Research LLC	Prodrugs of fulvestrant
US20230255974A1 (en) *	2020-02-29	2023-08-17	The University Of Vermont	Use of thyromimetics for the treatment of cancer

2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko active IP Right Grant
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en active IP Right Grant
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
2003
- 2003-05-27 HK HK03103770A patent/HK1051498A1/xx not_active IP Right Cessation
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20030007501A (ko)	2003-01-23
JP2003528919A (ja)	2003-09-30
BR0109789A (pt)	2003-01-21
RU2265438C2 (ru)	2005-12-10
NO329949B1 (no)	2011-01-31
IL151932A0 (en)	2003-04-10
GB0008172D0 (en)	2000-05-24
NO20024735D0 (no)	2002-10-02
CA2403608A1 (en)	2001-10-11
HUP0300339A2 (hu)	2003-06-28
KR100757764B1 (ko)	2007-09-12
ZA200207538B (en)	2003-12-19
IL151932A (en)	2007-07-04
NO20024735L (no)	2002-11-27
UA80388C2 (en)	2007-09-25
PL357936A1 (en)	2004-08-09
EE05026B1 (et)	2008-06-16
DE60113975D1 (de)	2006-02-23
ES2248300T3 (es)	2006-03-16
HU230064B1 (hu)	2015-06-29
EE200200574A (et)	2004-04-15
US20110183949A1 (en)	2011-07-28
CH1272195H1 (es)	2019-10-15
EP1272195B1 (en)	2005-10-12
DK1272195T3 (da)	2006-01-16
NZ539603A (en)	2008-02-29
ATE306270T1 (de)	2005-10-15
EP1586323A1 (en)	2005-10-19
CZ303096B6 (cs)	2012-04-04
EP1272195A1 (en)	2003-01-08
AU4437201A (en)	2001-10-15
IS2869B (is)	2014-03-15
DE60113975T2 (de)	2006-06-22
IS6576A (is)	2002-10-01
HUP0300339A3 (en)	2009-01-28
WO2001074366A1 (en)	2001-10-11
AU2001244372B2 (en)	2006-02-16
HK1051498A1 (en)	2003-08-08
MXPA02009744A (es)	2004-02-26
CZ20023309A3 (cs)	2003-02-12
US20030158166A1 (en)	2003-08-21
CN1431905A (zh)	2003-07-23
SK14292002A3 (sk)	2003-08-05
PL201175B1 (pl)	2009-03-31

Legal Events

Date	Code	Title	Description
2021-05-26	MK4A	Patent expired	Expiry date: 20210402

Publication	Publication Date	Title
US20110183949A1 (en)	2011-07-28	Use of Fulvestrant in the Treatment of Resistant Breast Cancer
Paridaens et al.	2003	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
US20240000785A1 (en)	2024-01-04	Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
DE602004002591T2 (de)	2007-08-09	Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
Mauriac et al.	2003	Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
Palomba et al.	2005	Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women
Joffe et al.	2007	Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report.
AU2001244372A1 (en)	2002-01-03	Use of fulvestrant in the treatment of resistant breast cancer
Lee et al.	2021	Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double‐Blind, Placebo‐Controlled Phase II Trial
Hirvonen et al.	1995	Can progestin be limited to every third month only in postmenopausal women taking estrogen?
HRP20120084A2 (hr)	2012-04-30	FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE
Casper	2000	Estrogen with interrupted progestin HRT: a review of experimental and clinical studies
Ramanadhan et al.	2020	Pharmacokinetics of hormonal contraception in individuals with obesity: a review
KR20070006543A (ko)	2007-01-11	확장된 경피 피임제 투약 계획
i Alsina et al.	0	Selective Estrogen Receptor Modulators. Antonio Cano
Kothari et al.	2010	The Treatment of Advanced Breast Cancer: Focus on Fulvestrant.